News headlines about Supernus Pharmaceuticals (NASDAQ:SUPN) have trended somewhat positive this week, Accern reports. The research group identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Supernus Pharmaceuticals earned a coverage optimism score of 0.22 on Accern’s scale. Accern also assigned news articles about the specialty pharmaceutical company an impact score of 46.2490379937036 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Shares of SUPN stock traded up $1.05 on Tuesday, reaching $45.20. The stock had a trading volume of 830,489 shares, compared to its average volume of 707,298. The company has a market cap of $2,360.40, a P/E ratio of 35.87 and a beta of 1.11. Supernus Pharmaceuticals has a 1 year low of $29.55 and a 1 year high of $50.04.
Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $0.44 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.26 by $0.18. The firm had revenue of $88.44 million for the quarter, compared to the consensus estimate of $87.84 million. Supernus Pharmaceuticals had a return on equity of 28.07% and a net margin of 18.95%. sell-side analysts expect that Supernus Pharmaceuticals will post 1.85 earnings per share for the current year.
In related news, VP Padmanabh P. Bhatt sold 20,000 shares of Supernus Pharmaceuticals stock in a transaction on Monday, January 22nd. The stock was sold at an average price of $48.04, for a total transaction of $960,800.00. Following the transaction, the vice president now directly owns 32,500 shares in the company, valued at $1,561,300. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Victor Vaughn sold 15,000 shares of Supernus Pharmaceuticals stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $42.04, for a total value of $630,600.00. Following the transaction, the vice president now owns 24,344 shares in the company, valued at $1,023,421.76. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 110,750 shares of company stock worth $4,927,923. Company insiders own 6.70% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Price” was reported by BBNS and is owned by of BBNS. If you are reading this news story on another publication, it was copied illegally and republished in violation of international copyright law. The original version of this news story can be viewed at https://baseballnewssource.com/2018/04/03/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-supernus-pharmaceuticals-supn-share-price/2015407.html.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.